Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread

NCT02196181 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

280

Enrollment

NIH

Sponsor class

Conditions

Stage III Cutaneous Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7
Unresectable Melanoma

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
DRUG: Dabrafenib Mesylate
PROCEDURE: Echocardiography Test
PROCEDURE: Multigated Acquisition Scan
PROCEDURE: Positron Emission Tomography
DRUG: Trametinib Dimethyl Sulfoxide

Sponsor

National Cancer Institute (NCI)